Study design
REACH was a multi-site, two-arm, randomized, open-label, crossover Phase 2a trial (ClinicalTrials.gov: NCT03593655) that aimed to enroll ˜300 participants across four sites in Africa (Kampala, Uganda; Harare, Zimbabwe; and Cape Town and Johannesburg, South Africa). Participants were randomized (1:1) to one of two sequences of product use: using the ring for 24 weeks and then switching to oral PrEP for a second 24 weeks or using oral PrEP for 24 weeks and then switching to the ring (